Jannah Theme License is not validated, Go to the theme options page to validate the license, You need a single license for each domain name.

Moderna Covid combination and flu vaccine show positive data

Arthur Widak | Nuphoto | Getty Images

Modern On Wednesday, its combination vaccine targeting Covid and flu will move into a final-stage trial in adults 50 and older this year after showing positive results in an early-to-mid-stage study.

The biotech company hopes its shot, mRNA-1083, can gain approval from regulators in 2025.

Moderna and other vaccine makers like Pfizer I think combination vaccines will simplify what people can do to protect themselves against respiratory viruses that typically appear around the same time of year.

“Combination vaccines offer an important opportunity to improve the consumer and provider experience, increase compliance with public health recommendations, and bring value to health systems,” said Stéphane Bancel, CEO of Moderna, in a press release.

“We are excited to move respiratory combination vaccines into Phase 3 of development and look forward to working with public health officials to address the significant seasonal threat these viruses pose to people,” he said. he adds.

The mRNA-1083 injection generated an immune response similar to or superior to two influenza vaccines currently available from GlaxoSmithKline in early or mid-stage clinical trials.

Moderna’s combination vaccine also produced a similar immune response to its bivalent Covid vaccine, which targets the BA.4 and BA.5 omicron variants and the original strain of the virus.

The trial evaluated the combined injection in two different age groups: people aged 50 to 64 and participants aged 65 to 79.

Safety data for mRNA-1083 was similar to that of the standalone Covid vaccine, according to Moderna. No new safety concerns have been identified with the combination vaccine.

Moderna is also developing a combination shot targeting influenza and RSV, as well as another vaccine targeting all three respiratory viruses: Covid, influenza and RSV.

Meanwhile, Pfizer and BioNTech are also developing a vaccine that targets both Covid and influenza. The companies launched a phase one trial for this vaccine in November and have said they plan to launch it in 2024 or later.

cnbc Business

Back to top button